A recent study involving over 60,000 men highlights potential risks associated with simultaneously taking erectile dysfunction (ED) drugs, specifically phosphodiesterase-5 inhibitors (PDE5i), along with nitrates, a common medication for chest pain. The study, published in the Journal of the American College of Cardiology, reveals an increased risk of negative health outcomes, including heart failure and early death.
The senior author of the study, Dr. Daniel Peter Andersson from the Karolinska Institute in Stockholm, emphasizes the importance of careful consideration before prescribing PDE5i to men receiving nitrate treatment. The study aims to draw attention to the need for further research into the effects of ED drugs on individuals with cardiovascular disease.
Despite existing controversy surrounding the simultaneous use of PDE5i and nitrates due to their potential to induce low blood pressure, the study indicates a growing trend of requests for ED drugs from men with cardiovascular diseases. The research involved 61,487 men with stable coronary artery disease and a history of myocardial infarction, who had received prescriptions for nitrates.
Participants treated with both nitrates and PDE5i showed a slightly higher risk of premature death from all causes compared to those treated with nitrates alone. Additionally, the combination group had double the risk of undergoing revascularization during the follow-up period.
Dr. Howard C. Herrmann from the University of Pennsylvania notes that while the findings are not surprising, the study serves as a warning to physicians about co-prescribing these medications. However, he points out the need for caution due to the study’s limitations, including a lack of detailed information on how patients took both medications and the absence of causality proof.
Patients using PDE5i and nitrates are advised to discuss alternative ED treatment options with their physicians and be informed about the timing of medication intake. Seeking medical attention is crucial if angina occurs after taking a PDE5i, emphasizing the importance of patient education and communication with healthcare providers.
